Philip Morris International Inc. Presents at Barclays Global Consumer Staples Conference
2015年9月9日 - 2:15AM
ビジネスワイヤ(英語)
Regulatory News:
Philip Morris International Inc.’s (NYSE / Euronext Paris: PM)
Chief Financial Officer, Jacek Olczak, will address investors today
at the Barclays Global Consumer Staples Conference in Boston.
The presentation and Q&A session are being webcast live, in
a listen-only mode, beginning at approximately 1:30 p.m. ET, at
www.pmi.com/webcasts. Highlights of the presentation include
updates on the company’s July year-to-date performance in key
geographies, as well as the commercialization and clinical
assessment of its reduced-risk product, iQOS.
“Our third quarter is off to a positive start, and this augurs
well for the balance of the year. Robust fundamentals have driven
favorable cigarette volume and share performance,” said Jacek
Olczak, Chief Financial Officer. “iQOS is performing at or above
our expectations and we are very encouraged by the results of our
clinical studies thus far.”
An archived copy of the webcast will be available at
www.pmi.com/webcasts until 5:00 p.m. ET on Wednesday, October 7,
2015. Remarks and slides will also be available at
www.pmi.com/presentations.
Philip Morris International
Inc.
Philip Morris International Inc. (PMI) is the leading
international tobacco company, with six of the world's top 15
international brands, including Marlboro, the number one cigarette
brand worldwide. PMI's products are sold in more than 180 markets.
In 2014, the company held an estimated 15.6% share of the total
international cigarette market outside of the U.S., or 28.6%
excluding the People's Republic of China and the U.S. For more
information, see www.pmi.com.
Reduced-Risk Products ("RRPs") is the term the company uses to
refer to products with the potential to reduce individual risk and
population harm in comparison to smoking combustible tobacco
products such as cigarettes. One of our strategic priorities is to
develop, assess and commercialize a portfolio of innovative RRPs.
Our RRPs are in various stages of development and
commercialization, and we are conducting extensive and rigorous
scientific studies to determine whether they reduce exposure to
harmful and potentially harmful constituents and ultimately reduce
disease risk, compared to cigarettes. Any claims we make are based
on a full set of data from the relevant scientific studies and may
also be subject to government review and approval, as is the case
in the U.S. today.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150908006124/en/
Investor Relations:New York: +1 (917) 663 2233Lausanne: +41
(0)58 242 4666orMedia:Lausanne: +41 (0)58 242 4500
P M I (NYSE:PMI)
過去 株価チャート
から 5 2024 まで 6 2024
P M I (NYSE:PMI)
過去 株価チャート
から 6 2023 まで 6 2024